Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$456.35 4.64 (1.01%) as of 4:30 Fri 10/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 137,634,000
Market Cap: 62.81(B)
Last Volume: 969,086 Avg Vol: 770,169
52 Week Range: $224.32 - $482.13
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  529
Guru Rank Value     : 3.6
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 4 36
Total Buy Value $0 $0 $1,211 $10,363
Total People Bought 0 0 1 1
Total Buy Transactions 0 0 1 2
Total Shares Sold 79,068 141,291 261,099 494,932
Total Sell Value $35,525,752 $54,194,136 $86,981,015 $137,201,444
Total People Sold 8 8 10 12
Total Sell Transactions 10 14 44 69
End Date 2025-07-06 2025-04-04 2024-10-04 2023-10-05

   
Records found: 523
  Page 1 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Garg Pushkal EVP Chief R&D   •       –      –    2025-10-03 4 AS $449.99 $1,364,387 D/D (3,022) 20,221     -
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-10-02 4 S $446.53 $1,103,451 D/D (2,441) 25,231     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-10-02 4 S $446.53 $1,727,284 D/D (3,821) 54,052     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-10-02 4 S $446.53 $4,034,085 D/D (8,924) 65,409     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-10-02 4 S $446.53 $635,126 D/D (1,405) 27,438     -
   Garg Pushkal EVP Chief R&D   •       –      –    2025-10-02 4 AS $446.53 $1,327,675 D/D (2,937) 23,243 -1%     
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-10-01 4 A $0.00 $0 D/D 4,953 27,672     -
   Supran Bryan EVP, CLO and Secretary   •       –      –    2025-10-01 4 A $0.00 $0 D/D 13,026 13,026     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-10-01 4 A $0.00 $0 D/D 7,752 57,873     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-10-01 4 A $0.00 $0 D/D 18,112 74,333     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-10-01 4 A $0.00 $0 D/D 2,851 28,843     -
   Garg Pushkal EVP Chief R&D   •       –      –    2025-10-01 4 A $0.00 $0 D/D 5,959 26,180     -
   Reitan Colleen F Director   –       •      –    2025-09-09 4 AS $457.44 $8,416,730 D/D (18,000) 775 -5%     
   Reitan Colleen F Director   –       •      –    2025-09-09 4 OE $100.65 $1,811,700 D/D 18,000 18,775     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-08-29 4 AS $445.53 $1,557,649 D/D (3,474) 25,992 2%     
   Garg Pushkal EVP Chief R&D   •       –      –    2025-08-19 4 AS $455.41 $666,987 D/D (1,455) 20,221 -0%     
   Bonney Michael W Director   –       •      –    2025-08-18 4 AS $450.00 $5,062,500 D/D (11,250) 16,804 -0%     
   Bonney Michael W Director   –       •      –    2025-08-18 4 OE $70.20 $789,750 D/D 11,250 28,054     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-08-18 4 S $447.98 $1,030,727 D/D (2,274) 50,121 -1%     
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-08-18 4 S $447.98 $632,759 D/D (1,396) 22,719 -1%     
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-08-18 4 S $447.98 $632,759 D/D (1,396) 29,466 -1%     
   Garg Pushkal EVP Chief R&D   •       –      –    2025-08-18 4 AS $447.98 $632,759 D/D (1,396) 21,676 -0%     
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-08-18 4 S $447.98 $3,163,346 D/D (6,979) 56,221 -1%     
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-08-15 4 A $0.00 $0 D/D 4,644 52,395     -
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-08-15 4 A $0.00 $0 D/D 2,851 24,115     -
  523 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us